Halozyme Therapeutics’ (HALO) Buy Rating Reiterated at Benchmark

Benchmark reiterated their buy rating on shares of Halozyme Therapeutics (NASDAQ:HALO – Free Report) in a research report released on Thursday morning,Benzinga reports. The brokerage currently has a $75.00 target price on the biopharmaceutical company’s stock. A number of other research analysts also recently issued reports on HALO. Piper Sandler boosted their price objective on […]